Clinical-stage biotech developing proprietary continuous low-dose drug-delivery systems (subcutaneous, oral, transdermal, on‑body) to maintain 24‑hour optimal drug levels and improve efficacy and tolerability. Targeting oncology patients (multiple myeloma, CLL, lymphoma, solid tumors) with a lead program delivering continuous low-dose lenalidomide to enable longer, more tolerable therapy.